VA
VERA icon

Verdad Advisers’s Vera Therapeutics VERA Stock Holding History

Verdad Advisers’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
23,487
+13,306
+131% +$496K 0.97% 26
2026
Q1 		$410K Buy
+10,181
New +$439K 0.46% 78

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Verdad Advisers's VERA Position: Q2 2026 in Review

Verdad Advisers increased its Vera Therapeutics (VERA) stake by 131% in Q2 2026, buying an estimated $496K and bringing the position to 23,487 shares worth $1.01M. The position accounts for 0.97% of the portfolio, ranked #26.

Verdad Advisers first reported a position in VERA in Q1 2026 and has held it in 2 quarters since. 220 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Verdad Advisers held 23,487 shares of Vera Therapeutics worth $1.01M as of Q2 2026.
  • Verdad Advisers bought 13,306 Vera Therapeutics shares in Q2 2026, an estimated $496K.
  • Vera Therapeutics made up 0.97% of Verdad Advisers's portfolio in Q2 2026, its #26 holding.
  • Verdad Advisers first reported a position in Vera Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 220 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.